IMMUN TROMBOTSITOPENIYADA GEMOSTAZ BUZILISHLARI VA ULARNING KLINIK AHAMIYATI
Ключевые слова:
qon ivishi, immun trombotsitopeniya, trombotsit funksiyasini baholash testlariАннотация
Immun trombotsitopeniya (ITP) yuqori darajada geterogen kasallik bo‘lib, og‘ir trombotsitopeniyaga ega bemorlarning faqat bir qismida jiddiy qon ketish rivojlanadi. Shu bilan birga, ITP tromboz rivojlanish xavfining paradoksal ravishda oshishi bilan ham bog‘liq. Ushbu maqolada ITP bilan og‘rigan bemorlarda qayd etilgan gemostaz tizimidagi turli o‘zgarishlar ko‘rib chiqiladi. Ma’lumotlar trombotsitlarning bazal faollashuvi oshganini, trombotsit reaktivligi esa pasayganini, biroq umumiy trombotsit funksiyasi ortganini ko‘rsatadi. Trombotsitlarning faollashgan holati va endoteliy disfunksiyasi qon ivish tizimining faollashuviga olib keladi.
Библиографические ссылки
Neunert C, Noroozi N, Norman G, Buchanan GR, Goy J, Nazi I, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2015;13:457–64. https://doi.org/10.1111/jth.12813
Arnold DM. Bleeding complications in immune thrombocytopenia. Hematology. 2015;2015:237–42. https://doi.org/10.1182/asheducation-2015.1.237
Nørgaard M, Cetin K, Maegbaek ML, Kristensen NR, Ghanima W, Bahmanyar S, et al. Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population-based cohort study. Br J Haematol. 2016;174:639–42. https://doi.org/10.1111/bjh.13787
Doobaree IU, Nandigam R, Bennett D, Newland A, Provan D. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Eur J Haematol. 2016;97:321–30. https://doi.org/10.1111/ejh.12777
Provan D, Semple JW. Recent advances in the mechanisms and treatment of immune thrombocytopenia. eBioMedicine. 2022;76:103820. https://doi.org/10.1016/j.ebiom.2022.103820
Audia S, Mahévas M, Nivet M, Ouandji S, Ciudad M, Bonnotte B. Immune thrombocytopenia: recent advances in pathogenesis and treatments. HemaSphere. 2021;5:e574. https://doi.org/10.1097/HS9.0000000000000574
Yazdanbakhsh K, Provan D, Semple JW. The role of T cells and myeloid-derived suppressor cells in refractory immune thrombocytopenia. Br J Haematol. 2023;203:54–61. https://doi.org/10.1111/bjh.19079
Altahan RM, Mathews N, Bourguignon A, Tasneem S, Arnold DM, Lim W, et al. Evaluation of a diagnostic platelet aggregation test strategy for platelet rich plasma samples with low platelet counts. Int J Lab Hematol. 2024;46:362–74. https://doi.org/10.1111/ijlh.14216
Nishiura N, Kashiwagi H, Akuta K, Hayashi S, Kato H, Kanakura Y, et al. Reevaluation of platelet function in chronic immune thrombocytopenia: impacts of platelet size, platelet-associated anti-αIIbβ3 antibodies and thrombopoietin receptor agonists. Br J Haematol. 2020;189:760–71. https://doi.org/10.1111/bjh.16439
van Bladel ER, Laarhoven AG, van der Heijden LB, Heitink-Polle´ KM, Porcelijn L, van der Schoot CE, et al. Functional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts. Blood. 2014;123:1556–63. https://doi.org/10.1182/blood-2013-08-519686
Mishra K, Jandial A, Sandal R, Tolios A, Eichelberger B, Kaider A, et al. Bleeding risk assessment in immune thrombocytopenia. Ann Hematol. 2023;102:3007–14. https://doi.org/10.1007/s00277-023-05466-1
Panzer S, Rieger M, Vormittag R, Eichelberger B, Dunkler D, Pabinger I. Platelet function to estimate the bleeding risk in autoimmune thrombocytopenia. Eur J Clin Invest. 2007;37:814–9. https://doi.org/10.1111/j.1365-2362.2007.01855.x
Panzer S, Höcker L, Rieger M, Vormittag R, Koren D, Dunkler D, et al. Agonist-inducible platelet activation in chronic idiopathic autoimmune thrombocytopenia. Eur J Haematol. 2007;79:198–204. https://doi.org/10.1111/j.1600-0609.2007.00900.x
Psaila B, Bussel JB, Linden MD, Babula B, Li Y, Barnard MR, et al. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012;119:4066–72. https://doi.org/10.1182/blood-2011-11-393900
Haselboeck J, Pabinger I, Ay C, Koder S, Panzer S. Platelet activation and function during eltrombopag treatment in immune thrombocytopenia. Ann Hematol. 2012;91:109–13. https://doi.org/10.1007/s00277-011-1249-5
Ignatova AA, Suntsova EV, Pshonkin AV, Martyanov AA, Ponomarenko EA, Polokhov DM, et al. Platelet function and bleeding at different phases of childhood immune thrombocytopenia. Sci Rep. 2021;11:9401. https://doi.org/10.1038/s41598-021-88900-6
Cahill MR, Macey MG, Cavenagh JD, Newland AC. Protein A immunoadsorption in chronic refractory ITP reverses increased platelet activation but fails to achieve sustained clinical benefit. Br J Haematol. 1998;100:358–64. https://doi.org/10.1046/j.1365-2141.1998.00568.x
Panzer S, Höcker L, Vormittag R, Rieger M, Koren D, Dunkler D, et al. Flow cytometric evaluation of platelet activation in chronic autoimmune thrombocytopenia. Pediatr Blood Cancer. 2006;47:694–6. https://doi.org/10.1002/pbc.21000
Suntsova EV, Demina IM, Ignatova AA, Ershov NM, Trubina NM, Dobrynina J, et al. Bleeding tendency and platelet function during treatment with romiplostim in children with severe immune thrombocytopenic purpura. Int J Hematol. 2017;105:841–8. https://doi.org/10.1007/s12185-017-2207-3
Connor DE, Ma DDF, Joseph JE. Flow cytometry demonstrates differences in platelet reactivity and microparticle formation in subjects with thrombocytopenia or thrombocytosis due to primary haematological disorders. Thromb Res. 2013;132:572–7. https://doi.org/10.1016/j.thromres.2013.09.009
